Cessatech A/S announced topline results of its Phase 1 bioavailability trial (0204) with CT001 in healthy adults (NCT04807335). In this randomised, three-treatment, three-period, single dose crossover trial 15 healthy subjects were allocated to treatment with CT001, IV ketamine, and IV sufentanil at three different dosing visits. The objective of the trial was to investigate the absorption of CT001 across nasal mucosa (also known as bioavailability) compared to marketed intravenous solutions of the two analgesic drugs composing CT001.

Additionally, the safety and tolerability of CT001 was assessed during the trial. Approximately 40% of sufentanil and 50% of ketamine was absorbed into the systemic circulation when administered via the nasal spray as compared to intravenous infusions in the subjects, meeting the objective of the trial. The reported side effects were of mild severity and CT001 was assessed to be safe and well tolerated in the trial.

The most common side effects reported for CT001 was headache.